Relationship-level analysis of drug users' anticipated changes in risk behavior following HIV vaccination

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Formative research into the behavioral factors surrounding HIV vaccine uptake is becoming increasingly important as progress is made in HIV vaccine development. Given that the first vaccines on the market are likely to be partially effective, risk compensation (i.e., increased risk behavior following vaccination) may present a concern. This study characterized the relationships in which HIV vaccine-related risk compensation is most likely to occur using dyadic data collected from people who use drugs, a high-risk group markedly underrepresented in extant literature. Data were collected from 433 drug users enrolled in a longitudinal study in the USA. Respondents were asked to provide the first name and last initial of individuals with whom they had injected drugs and/or had sex during the past six months. For each partner, respondents reported their likelihood of increasing risk behavior if they and/or their partner received an HIV vaccine. Using generalized linear mixed models, relationship-level correlates to risk compensation were examined. In bivariate analysis, risk compensation was more likely to occur between partners who have known each other for a shorter time (odds ratio [OR] = 0.95, 95% confidence interval [CI]: 0.90-0.99, p = 0.028) and between those who inject drugs and have sex together (OR = 2.52, CI: 1.05-6.04, p = 0.039). In relationships involving risk compensation, 37% involved partners who had known each other for a year or less compared to only 13% of relationships not involving risk compensation. Adjusting for other variables, duration (OR: 0.95, CI: 0.90-1.00, p = 0.033) was associated with risk compensation intent. These analyses suggest that risk compensation may be more likely to occur in less established relationships and between partners engaging in more than one type of risk behavior. These data provide further support for the need to expand measures of risk compensation in HIV vaccine preparedness studies to assess not only if people will change their behavior, but also with whom.

Original languageEnglish
Pages (from-to)1000-1004
Number of pages5
JournalAIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV
Volume27
Issue number8
DOIs
StatePublished - Aug 3 2015

Bibliographical note

Publisher Copyright:
© 2015 Taylor & Francis.

Funding

This work was supported by the National Institute on Drug Abuse [grant number R01DA024598], [grant number R01DA033862]; the National Center for Research Resources; and the National Center for Advancing Translational Sciences at the National Institutes of Health [grant number UL1TR000117].

FundersFunder number
National Institutes of Health (NIH)
National Institute on Drug AbuseR01DA033862, R01DA024598
National Center for Research Resources
National Center for Advancing Translational Sciences (NCATS)UL1TR000117, TL1TR000115

    Keywords

    • HIV vaccine
    • condom use
    • injection drug use
    • risk compensation
    • social network

    ASJC Scopus subject areas

    • Health(social science)
    • Social Psychology
    • Public Health, Environmental and Occupational Health

    Fingerprint

    Dive into the research topics of 'Relationship-level analysis of drug users' anticipated changes in risk behavior following HIV vaccination'. Together they form a unique fingerprint.

    Cite this